- Home
- ZCMD vs NRXP Comparison
ZCMD vs NRXP Comparison
Compare ZCMD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- NRXP
- Stock Information
- Founded
- ZCMD 2012
- NRXP 2015
- Country
- ZCMD China
- NRXP United States
- Employees
- ZCMD N/A
- NRXP N/A
- Industry
- ZCMD Other Consumer Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- NRXP Health Care
- Exchange
- ZCMD Nasdaq
- NRXP Nasdaq
- Market Cap
- ZCMD 29.0M
- NRXP 32.6M
- IPO Year
- ZCMD 2020
- NRXP N/A
- Fundamental
- Price
- ZCMD $1.14
- NRXP $3.21
- Analyst Decision
- ZCMD
- NRXP Strong Buy
- Analyst Count
- ZCMD 0
- NRXP 4
- Target Price
- ZCMD N/A
- NRXP $28.50
- AVG Volume (30 Days)
- ZCMD 506.1K
- NRXP 202.4K
- Earning Date
- ZCMD 01-01-0001
- NRXP 08-13-2025
- Dividend Yield
- ZCMD N/A
- NRXP N/A
- EPS Growth
- ZCMD N/A
- NRXP N/A
- EPS
- ZCMD N/A
- NRXP N/A
- Revenue
- ZCMD $15,864,773.00
- NRXP N/A
- Revenue This Year
- ZCMD N/A
- NRXP N/A
- Revenue Next Year
- ZCMD N/A
- NRXP N/A
- P/E Ratio
- ZCMD N/A
- NRXP N/A
- Revenue Growth
- ZCMD N/A
- NRXP N/A
- 52 Week Low
- ZCMD $0.95
- NRXP $1.10
- 52 Week High
- ZCMD $2.97
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ZCMD 48.00
- NRXP 51.07
- Support Level
- ZCMD $1.13
- NRXP $3.12
- Resistance Level
- ZCMD $1.24
- NRXP $3.53
- Average True Range (ATR)
- ZCMD 0.11
- NRXP 0.18
- MACD
- ZCMD -0.01
- NRXP -0.05
- Stochastic Oscillator
- ZCMD 21.84
- NRXP 41.82
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.